Prota Therapeutics, the developer of oral immunotherapies to treat food allergies, has partnered with Chr. Hansen. The partnership will assess the world’s best documented probiotic strain, LGG®, in a Phase III clinical trial to develop a treatment for peanut allergy.

As the conversion wave from synthetic to natural colors continues to rise in the US market, Chr. Hansen gears up for the future

"We are satisfied with the progress in the first half of the year, and we maintain our overall guidance for the full year,” says CEO Cees de Jong

Pocket size, NIR spectrometer transforms feed analysis by enabling real-time, on-farm forage analysis - Chr. Hansen equips their nutritionists and distributors first, followed by all customers.

Jørgen Erichsen, Executive Vice President of the Natural Colors Division, will leave the position as Executive Vice President effective today, 2 February 2018.

​EVP Christoffer Lorenzen has been appointed member of the Executive Board of Chr. Hansen Holding A/S.

Bioprotection continues to show impressive momentum

The Board of Directors of Chr. Hansen Holding A/S has today appointed Mauricio Graber as new Chief Executive Officer (CEO) as of 1 June 2018.

New sophisticated analytics technology helps cheesemakers increase overall value from the milk processed – Chr. Hansen obtains global distribution

Chr. Hansen’s Chief Executive Officer Cees de Jong has informed the Company that after having led Chr. Hansen as CEO for almost 5 years, he intends to pursue a career as a non-executive director outside Chr. Hansen in due course.